Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Abstract Background Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns of cabozantinib are not well characterized. Methods Patients with mRCC treated with cabozantinib between 2011 and 2019...

Descrición completa

Detalles Bibliográficos

Principais autores:	Chun Loo Gan, Shaan Dudani, J. Connor Wells, Frede Donskov, Sumanta K. Pal, Nazli Dizman, Nityam Rathi, Benoit Beuselinck, Flora Yan, Aly‐Khan A. Lalani, Aaron Hansen, Bernadett Szabados, Guillermo deVelasco, Ben Tran, Jae Lyun Lee, Ulka N. Vaishampayan, Georg A. Bjarnason, Mathushan Subasri, Toni K. Choueiri, Daniel Y. C. Heng
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2021-02-01
Series:	Cancer Medicine
Assuntos:	cabozantinib first line fourth line IMDC real‐world renal‐cell carcinoma
Acceso en liña:	https://doi.org/10.1002/cam4.3717
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!